Pancreaticc cancer is the fourth leading cause of cancer-related death in the Western world. 1 The overalll 5-year survival is less than 4% and has hardly improved over the last two decades. ? The majorr cause of this poor prognosis is its relatively late detection. Around 80% of patients presenting withh pancreatic carcinoma have locally spread or metastasized disease, which makes a curative resectionn impossible. A successful pancreatico-duodenectomy improves the 5-year survival rate too percentages varying from 8 to 21 %. 3 A subset of the operable patients with favorable prognostic factorss such as negative lymph nodes, negative margins, and tumors smaller than 3 cm even havee a 40% chance to survive the first 5 years after surgery. 4 ' 6 Likee in other cancer types, early detection of pancreatic carcinoma is therefore crucial for a better patientt survival. Early detection is hampered mostly by the late presentation of non-specific symptoms.. Optimizing existing diagnostic methods using specific molecular genetic alterations accompanyingg pancreatic carcinogenesis and surveillance of patients at risk for developing pancreaticc carcinoma are potential ways to advance the diagnosis.
Thee K-ras oncogene is mutated in more than 90% of pancreatic carcinomas. Since virtually all Krasras mutations are confined to codon 12, they are relatively easy to detect. 79 Therefore several studiess have focused on the clinical utility of K-ras mutations in the early detection of pancreatic carcinoma. 100 ' 8 In a previous study we evaluated the additional diagnostic value of K-ras codon 12 mutationss in brush cytology specimens obtained during endoscopic retrograde cholangiopancreatographyy (ERCP) from 312 consecutive patients with an extrahepatic biliary stenosis suspiciouss for cancer. 13 In that study, K-ras codon 12 mutation analysis proved to be a useful methodd to improve the diagnostic sensitivity of conventional cytology to detect malignancy. The sensitivityy increased from 36% for conventional cytology alone, to 62% for conventional cytology inn combination with K-ras mutation analysis. Thus, K-ras mutations could be an attractive tumor markerr and may be useful for future screening purposes.
However,, in that same study eight of the 312 (2.6%) patients harbored a K-ras mutation while malignancyy as the cause of the extrahepatic biliary stenosis could not be confirmed. Also after a mediann follow-up of 65 months these patients had to be considered as true false positives. 19 Althoughh a false-positive result might be infrequent, the specificity of the K-ras mutation analysis remainss a concern, because the consequences of unnecessary surgical resection are unacceptable.
K-rass mutations have also been reported in the precursor lesions of pancreatic cancer, the socalledd pancreatic intraepithelial neoplasia (PanIN) lesions.
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' 19 The presence of K-ras mutations in brushh cytology and bile from patients without a pancreatic or other periampullary neoplastic diseasee could hinder its diagnostic use. However, patients who underwent an ERCP for periampullary diseasee suspicious for cancer will introduce a selection bias when used as study population to evaluatee K-ras mutations, even if these patients do not have malignancy; this method does not providee an estimate about prevalence of K-ras mutations in the non-diseased general population, i.e.. specificity. The techniques required to obtain brush cytology or bile are invasive and not without risks,, and therefore not suitable to perform in a normal healthy control group.
Thee so-called "epidemiological necropsy" study design provides a way to estimate trends and occurrencee of non-manifest disease or undetected abnormalities in the general population and cann be regarded as a screening survey to assess the reservoir of abnormalities indicative for a certainn disease among persons in whom this particular disease is not expected. The main principle off this design is to investigate necropsies without the disease under study and without risk factorss for that particular disease, hereby avoiding selection bias. 30 Bias due to the nature of a hospitall population is avoided by using incidental data from necropsies carried out for unrelated disease.
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'' Meanwhile, standardization by age, gender, and co-morbidity reduces demographic bias.. This is a potentially valuable method not only to help distinguish the true occurrence rates off disease from the changes attributable to improved diagnostic detection, but also to determine thee specificity of clinical analyses.
Thee aim of the current study was to estimate the prevalence of K-ras mutations in brush cytology andd bile in the general population in order to enhance the understanding of its utility as a molecularr marker for periampullary cancer by using the "epidemiologic necropsy" study design.
Studyy group
Alll necropsies of patients older than one year performed at the Academic Medical Center in Amsterdamm between March 1996 and March 1997, and at the Pathologisch Anatomisch Laboratoriumm (PAL) in Enschede between March and September 1996 were prospectively included.
Clinicall and pathology data were retrieved including patient characteristics, general medical history, historyy of cancer, smoking and drinking habits when available, reason for admission, clinical cause off death and all pathology investigations performed. According to the "epidemiologic necropsy" studyy design all necropsies with evidence or suspicion of the studied disease before death were excludedd from this study. Therefore the following two exclusion criteria were used: (1) necropsies onn patients with a history of pancreatic cancer or pancreatitis, and (2) necropsies on patients who weree referred to hospital for analysis of symptoms that could be indicative for pancreatic disease.
Patientss were categorized by location of necropsy, gender, age group and cause of death.
Collectionn of material
Att necropsy, the stomach, duodenum, liver, biliary tract, pancreas and spleen were resected "en bloc".. After opening the duodenum, the Ampulla of Vater was localized. By squeezing the gall bladderr the bile present in the distal common bile duct was collected. After bile collection the firstt two centimeters of the distal common bile duct was brushed with an endocervical brush Thee brushed part of the distal common bile duct and the underlying pancreatic tissue was resected.
Thiss tissue was partly paraffin-embedded after formalin fixation and partly fresh-frozen and stored att .
Isolationn of DNA AA sample of 1 ml of both bile and brush cytology collections was used for DNA isolation. The sampless were spinned, the supernatant was removed, and the cell-pellet was incubated with proteinasee K at C for at least one hour. Proteinase K was inactivated by heating the samples att 96 C C. Pancreatic tissue was micro-dissected with a fine needle for DNA isolation.
K-rasK-ras codon 12 mutation analysis
DNAA was subjected to PCR amplification using primers centered around codon 12. One of the primerss introduces a restriction site in the PCR products derived from wild-type codon 12 alleles butt not in those derived from mutant codon 12 alleles. After digestion of the PCR products, a secondd round of PCR amplification is performed, yielding a PCR product enriched for K-ras codon 122 mutations. The resulting DNA products are denatured and dot-blotted onto nylon membranes andd subjected to allefe-specific oligonucleotide (ASO) hybrid-ization with radioactive labeled probes, specificc for each possible K-ras codon 12 mutation, followed by autoradiography. Cell suspensions withh mutant:wild type ratios of 1:100 and 1:1000 were used as positive controls in every PCR procedure.. The cell suspensions were made of the human colon cancer cell line SW 480 with a homozygouss GGT to GTT mutation at codon 12 of K-ras and the human colon cancer cell line HT 299 with wild type K-ras. Water was used as a negative control, placental DNA for non-specific hybridization.. All PCR products were hybridized with olignucleotides with the wild type sequence too control for amplification of the DNA samples. Enriched and non-enriched PCR products were dot-blottedd next to each other to check for the digestion and the mutant-enrichment. We previously validatedd this method using mutant enriched PCR with ASO hybridization by comparing it with sequencee analysis. 
Brushh cytology
Brushh cytology was not available in two necropsies, thus remaining 315 brush cytology samples Bilee was not available in 31 necropsies and DNA could not be amplified from 14 necropsies, thus leavingg 286 bile samples to be analyzed. Eighteen of 286 (6.3%) contained one or more K-ras codon 122 mutations. The most frequently detected K-ras mutation in bile was the GGT to GAT mutation in 77 of 18 (39%o) cases. Two different K-ras mutations were detected in the same bile of four necropsies.
Thee frequencies and type of mutations detected in the bile samples are listed in table 3.
InIn 16 necropsies both brush and bile contained one or more K-ras mutations, of which fifteen weree concordant. In ten necropsies the mutations detected in brush cytology were concordant (0.3%) ) (0.6%) ) (0.3%) ) (0.6%) ) (1.3%) ) (0.6%) ) (1.6%) ) (0.3%) ) (4.4%) ) (9.8%) ) (80.1%) ) (100%) ) Tablee 4 Frequency, type of mutations and characteristics of the 16 necropsies with a K-ras codon 12 mutation inn brush cytology and bile. In 15 necropsies at least one mutation in brush and bile was concordant. 
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withh the mutations in bile, while in five necropsies one of the two mutations in brush cytology wass concordant with the mutations in bile. In one necropsy the mutations detected in brush and bilee were not concordant (table 4). Ten of 16 (62%) patients with mutations in both brush and bilee died of cancer (mortality due to cancer in the total group was 112 of 317 (37%)).
PanINN lesions
Sixty-threee from the 66 (95%) randomly selected pancreata showed the presence of PanIN lesions. T  GTT T  GAT T  GAT,, CGT  GTT T  GTT,, CGT  GTT,, GAT GTT,, GAT GAT T GAT T Age--and sex-specific frequency distributions and estimate of prevalence Thee majority of necropsies, 139/317 (44%), fell into the age category 65-80 years (table 6). In thiss age category 38/139 (27%) necropsies showed a K-ras mutation in brush cytology, while 10/139(7.2%)) necropsies showed a K-ras mutation in the bile. When multiplied by the 1,649,851 subjectss in the age category 65-80 years in the general population of the year 2000, estimates of aa prevalence of 451,038 subjects with a K-ras mutation in brush cytology and 118,694 subjects withh a K-ras mutation in bile can be made. The estimated prevalence of K-ras mutation in brush cytologyy and bile is highest in the largest age category 40-64 years with 1,054,849 and 329,641 subjects,, respectively. By adding up the calculated prevalences in the different age categories, thee prevalence of K-ras mutations in the total, non-diseased general population of almost 16 millionn people in The Netherlands in the year 2000 can be estimated at 2.2 million (14%) in brush cytologyy and almost half a million (3%) in bile (table 6) .
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Thee total of 78/317 (25%) brush cytologies with a K-ras mutation consisted of 44/187 (24%) men thee prevalence of K-ras mutations in brush and bile could not be estimated based on gender, but in vieww of the above calculations a significant difference between genders seems unlikely.
Tablee 6. Prevalence of K-ras mutations in the study population divided over the different age categories and estimatee of the prevalence of K-ras mutations in the non-diseased population using data from the general populationn in 2000 Thee high prevalence of PanIN lesions in the disease-free pancreas in our study is comparable to findingss from other institutions. 2 " The spectrum of K-ras codon 12 mutations detected in the PanINN lesions in present study are in line with the spectrum of mutations observed in pancreatic carcinoma,, predominantly GGT to GAT and GGT to GTT mutations. 7 ' 8 This is in contrast with the findingss of a study performed by Tada et al. in 1995. 2 ' They reported high frequencies of GGT to TGT{37%)) and GGT to AGT(16%) mutations in "hyperplastic duct epithelium" from disease-free pancreata,, while these are very rare in pancreatic carcinoma. 7 The authors conclude that these typess of K-ras mutations have low potential for malignant transformation and that hyperplastic lesionss containing these mutations normally do not progress to invasive carcinoma. However, geographicall influence as well as methodological flaws are also known to account for the differencess in prevailing K-ras mutations.
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Twoo different mutations in the same sample were encountered in five pancreata, 13 brush cytologiess and four bile specimens. During microdissection the PanIN lesions were pooled, which mightt explain the occurrence of more than one mutation in the same sample. Different PanIN lesionss can contain different K-ras codon 12 mutations, although this has been described for one andd he same PanIN lesion as well. 37 Moreover, in 23 of 66 (35%) analyzed pancreata a K-ras mutationn was detected in the corresponding brush cytology or bile specimens while no mutation wass detected in the matching pancreatic tissue.
Thee "PanIN -pancreatic carcinoma" sequence shares similarities with the well-established adenomacarcinomaa sequence proposed for the development of colorectal cancer. 3839 In both tumor progressionn models precursor lesions are more prevalent in the older population. An age-related increasee of PanIN lesions, formerly called pancreatic duct hyperplasia, in the pancreas has long beenn recognized. 23J,0 ' !1 Furthermore, as described for the adenomaHcarcinoma sequence in the colorectum,, the progression from histologically normal pancreatic duct epithelium to invasive pancreaticc carcinoma is associated with an accumulation of genetic alterations. 28 - 46 This study showss that K-ras mutations also lack specificity for the more advanced PanIN lesions and infiltrating carcinoma,, and a high percentage of false positive results can be expected in a screening setting.
Ass suggested in a previous study, K-ras codon 12 mutation analysis can be of value in establishing aa diagnosis of pancreatic carcinoma in a selected group of symptomatic patients with a high a prioripriori chance. 13 The optimal molecular screening marker should have the quality of only identifying patientss with advanced PanIN lesions before invasive carcinoma has developed. Advanced PanIN lesionss imply a high risk for progression to carcinoma and curative surgery is still feasible in this pre-cancerouss phase. 43 ' 4743 Consequently, a gene or a panel of genes which are mutated later in thee pancreatic tumor progression model might be more effective as screening tool.
Inn conclusion, this study shows that K-ras codon 12 mutations can be expected in 14% of brush cytologyy and 3% of bile specimens from the non-diseased general population. In the autopsy populationn that served as study population for this estimate the K-ras mutations were all encounteredd in PanlN-1A or PanlN-1B lesions, which were present in 95% of randomly selected pancreata.. This suggests limited use of K-ras mutation analysis in the surveillance of patients at highh risk for periampullary cancer.
